ORYZON Reports First Dosing in Phase 1 Study of Alzheimer’s Drug Treatment
Oryzon Genomics recently announced the dosing of a first subject in its Phase 1 trial of oral LSD1-MAOB dual selective inhibitor ORY-2001, targeting memory loss and cognitive decline in Alzheimer’s disease. The single and multiple ascending dose study will evaluate the safety, tolerability, and pharmacokinetics of ORY-2001 in healthy subjects. The trial is randomized, double-blind,…